Actionable news
0
All posts from Actionable news
Actionable news in SRPT: Sarepta Therapeutics, Inc.,

10 Stocks Moving In Tuesday's Pre-Market Session

Invest with Confidence. Are you a financial professional? Stay on top of your portfolio with Benzinga Pro's real-time newsfeed and alerts and never miss a headline again.
Don't miss the chance to try it FREE today.


Gainers

Origin Agritech Ltd. SEED shares rose 22.37 percent to $2.79 in pre-market trading. Origin Agritech appointed Dr. William S. Niebur as new President and CEO.

Aratana Therapeutics Inc PETX shares rose 17.22 percent to $8.10 in pre-market trading as a deal with Elanco Animal Health was announced. Elanco is a division of Eli Lilly that focuses on animal health products such as Apralan, Coban, Hygromix, Maxiban and Micotil. Under terms of the deal, Elanco will have global exclusive rights to develop, market and commercialize Galliprant while they help co-promote Galliprant in the U.S. with Aratana.

Exelixis, Inc. EXEL rose 8.37 percent to $5.05 in pre-market trading. On Monday, Exelixis revealed the FDA has given its approval for its CABOMETYX (cabozantinib) tablets.

PACCAR Inc PCAR rose 3.50 percent to $58.01 in pre-market trading. PACCAR reported better-than-expected earnings for its first quarter.

JetBlue Airways Corporation JBLU rose 3.49 percent to $21.08 in pre-market trading as the company reported upbeat Q1 profit.

T-Mobile US Inc TMUS shares rose 2.84 percent to $42.35 in pre-market trading. T-Mobile US reported better-than-expected quarterly revenue and lifted its full-year forecast.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Losers

Sarepta Therapeutics Inc SRPT shares fell 45.42 percent to $8.16 in pre-market trading after a federal advisory panel voted that eteplirsen, its drug for the treatment of Duchenne muscular dystrophy (DMD), was not effective. The U.S. Food and Drug Administration voted 6-7 against the finding of substantial evidence that eteplirsen induces production of dystrophin to a level that is reasonably likely to predict clinical benefit.

Capital Product Partners L.P. CPLP shares fell 38.64 percent to $2.35 in pre-market trading. Capital Product Partners reported net income of $12.1 million on revenue of $58.0 million for the quarter ended March 31, 2016.

Eli Lilly and Co LLY shares fell 4 percent to $74.82 in pre-market trading. Eli Lilly reported downbeat Q1 earnings, but the company’s revenue exceeded analysts’ estimates.

Apple Inc. AAPL shares fell 0.72 percent to $104.32 in pre-market trading. Apple is scheduled to post quarterly earnings after the closing bell.

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.